VANCOUVER, Washington, March 13, 2020 (GLOBE NEWSW
Post# of 155485
(Total Views: 675)
Posted On: 03/13/2020 6:02:49 AM
VANCOUVER, Washington, March 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the appointment of Jacob P. Lalezari, M.D. as Interim Chief Medical Officer. Dr. Lalezari is currently leading CytoDyn’s immediate preparations to initiate a coronavirus (COVID-19) clinical trial and the Company will file a modified trial protocol on Friday, March 13.
Dr. Lalezari, currently Chief Executive Officer and Director of Quest Clinical Research in San Francisco, has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B &C, Influenza, RSV and cancer. Dr. Lalezari also serves as a leading clinician for CytoDyn’s HIV and mTNBC trials with leronlimab. Prior to joining Quest Clinical Research, Dr. Lalezari was Co-Director, HIV Clinical Research Center, Mt. Zion Medical Center at University of California, San Francisco. He has published several research papers and presented research at numerous international conferences. Dr. Lalezari holds a M.A. degree from the University of Virginia and earned his M.D. at the University of Pennsylvania.
Jacob P. Lalezari, M.D., commented, “I am excited to join the CytoDyn team in a leadership role to advance the therapeutic opportunities of leronlimab for so many potential indications. I have been deeply involved with CytoDyn for several years and most recently in its cancer studies, which are now producing unique and compelling results. We are also accelerating the opportunity to evaluate leronlimab as a treatment for coronavirus patients and are hopeful to initiate treatment to patients in the very near future.”
Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, stated: “We are very pleased that Dr. Lalezari has joined our Company at a very exciting time. Based upon his years of clinical experience working with leronlimab, he has a comprehensive understanding of the patient data from our HIV clinical trials for combination and monotherapy, and importantly, our current clinical trials with cancer patients. This understanding is of the highest importance to us.”
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the appointment of Jacob P. Lalezari, M.D. as Interim Chief Medical Officer. Dr. Lalezari is currently leading CytoDyn’s immediate preparations to initiate a coronavirus (COVID-19) clinical trial and the Company will file a modified trial protocol on Friday, March 13. Dr. Lalezari, currently Chief Executive Officer and Director of Quest Clinical Research in San Francisco, has served as a principal investigator for Phase I, II, and III clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV, HSV, Hepatitis B &C, Influenza, RSV and cancer. Dr. Lalezari also serves as a leading clinician for CytoDyn’s HIV and mTNBC trials with leronlimab. Prior to joining Quest Clinical Research, Dr. Lalezari was Co-Director, HIV Clinical Research Center, Mt. Zion Medical Center at University of California, San Francisco. He has published several research papers and presented research at numerous international conferences. Dr. Lalezari holds a M.A. degree from the University of Virginia and earned his M.D. at the University of Pennsylvania.
Jacob P. Lalezari, M.D., commented, “I am excited to join the CytoDyn team in a leadership role to advance the therapeutic opportunities of leronlimab for so many potential indications. I have been deeply involved with CytoDyn for several years and most recently in its cancer studies, which are now producing unique and compelling results. We are also accelerating the opportunity to evaluate leronlimab as a treatment for coronavirus patients and are hopeful to initiate treatment to patients in the very near future.”
Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, stated: “We are very pleased that Dr. Lalezari has joined our Company at a very exciting time. Based upon his years of clinical experience working with leronlimab, he has a comprehensive understanding of the patient data from our HIV clinical trials for combination and monotherapy, and importantly, our current clinical trials with cancer patients. This understanding is of the highest importance to us.”
(3)
(0)